CDRH has developed a novel risk-based strategy for designing pivotal trials for weight-loss devices, with plans to set the effectiveness endpoints based on adverse event rates observed in feasibility studies.
An FDA advisory panel signaled overall support for the vision, though the outside advisers told agency officials earlier this month...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?